Anti-SARS-CoV-2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID-19 vaccination regimens
Issued Date
2022-07-01
Resource Type
ISSN
17502640
eISSN
17502659
Scopus ID
2-s2.0-85125044604
Pubmed ID
35199966
Journal Title
Influenza and other Respiratory Viruses
Volume
16
Issue
4
Start Page
662
End Page
672
Rights Holder(s)
SCOPUS
Bibliographic Citation
Influenza and other Respiratory Viruses Vol.16 No.4 (2022) , 662-672
Suggested Citation
Kittikraisak W., Hunsawong T., Punjasamanvong S., Wongrapee T., Suttha P., Piyaraj P., Leepiyasakulchai C., Tanathitikorn C., Yoocharoen P., Jones A.R., Mongkolsirichaikul D., Westercamp M., Azziz-Baumgartner E., Mott J.A., Chottanapund S. Anti-SARS-CoV-2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID-19 vaccination regimens. Influenza and other Respiratory Viruses Vol.16 No.4 (2022) , 662-672. 672. doi:10.1111/irv.12975 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85778
Title
Anti-SARS-CoV-2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID-19 vaccination regimens
Author's Affiliation
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention
Armed Forces Research Institute of Medical Sciences, Thailand
Thailand Ministry of Public Health
Mahidol University
Phramongkutklao College of Medicine
Bamrasnaradura Infectious Diseases Institute
Phaholpolpayuhasena Hospital
Rayong Hospital
Centers for Disease Control and Prevention
Armed Forces Research Institute of Medical Sciences, Thailand
Thailand Ministry of Public Health
Mahidol University
Phramongkutklao College of Medicine
Bamrasnaradura Infectious Diseases Institute
Phaholpolpayuhasena Hospital
Rayong Hospital
Other Contributor(s)
Abstract
Background: We examined SARS-CoV-2 anti-spike 1 IgG antibody levels following COVID-19 vaccination (AstraZeneca [AZ], Sinovac [SV], Pfizer-BioNTech [PZ]) among Thai healthcare providers. Methods: Blood specimens were tested using enzyme-linked immunosorbent assay. We analyzed seven vaccination regimens: (1) one dose of AZ or SV, (2) two doses of homologous (2AZ, 2SV) or heterologous (1AZ + 1PZ) vaccines, and (3) three doses of heterologous vaccines (2SV + 1AZ, 2SV + 1PZ). Differences in antibody levels were assessed using Kruskal–Wallis statistic, Mann–Whitney test, or Wilcoxon matched-pairs signed-rank test. Antibody kinetics were predicted using fractional polynomial regression. Results: The 563 participants had median age of 39 years; 92% were female; 74% reported no underlying medical condition. Antibody levels peaked at 22–23 days in both 1AZ and 2SV vaccinees and dropped below assay's cutoff for positive (35.2 binding antibody units/ml [BAU/ml]) in 55 days among 1AZ vaccinees compared with 117 days among 2SV vaccinees. 1AZ + 1PZ vaccination regimen was highly immunogenic (median 2279 BAU/ml) 1–4 weeks post vaccination. 2SV + 1PZ vaccinees had significantly higher antibody levels than 2SV + 1AZ vaccinees 4 weeks post vaccination (3423 vs. 2105 BAU/ml; p-value < 0.01), and during weeks 5–8 (3656 vs. 1072 BAU/ml; p-value < 0.01). Antibodies peaked at 12–15 days in both 2SV + 1PZ and 2SV + 1AZ vaccinees, but those of 2SV + 1AZ declined more rapidly and dropped below assay's cutoff in 228 days while those of 2SV + 1PZ remained detectable. Conclusions: 1AZ + 1PZ, 2SV + 1AZ, and 2SV + 1PZ vaccinees had substantial IgG levels, suggesting that these individuals likely mounted sufficient anti-S1 IgG antibodies for possible protection against SARS-CoV-2 infection.